10-Q
Quarterly Report
ADIAL PHARMACEUTICALS, INC.
ADIL
NASDAQ
CIK: 1513525
File #: 001-38323
Balance Sheet
27 line items · 2 periods
XBRL
| Item | Jun 30, 2024 | Dec 31, 2023 |
|---|---|---|
ASSETS | ||
Current Assets: | ||
Cash and cash equivalents | 3,288,048 | 2,827,082 |
Prepaid research and development | 346,754 | — |
Prepaid expenses and other current assets | 188,600 | 371,597 |
Total Current Assets | 3,823,402 | 3,198,679 |
Intangible assets, net | 3,631 | 3,913 |
Equity method investment | 1,121,670 | 1,534,013 |
Equity Method Investments | 1,121,670 | 1,534,013 |
Total Assets | 4,948,703 | 4,736,605 |
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
Current Liabilities: | ||
Accounts payable | 316,726 | 103,325 |
Related Party | — | 24,062 |
Accrued expenses | 335,156 | 477,747 |
Related Party | 20,000 | 47,942 |
Total Current Liabilities | 671,882 | 653,076 |
Total Liabilities | 671,882 | 653,076 |
Stockholders’ Equity | ||
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 4,293,681 and 1,663,421 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively | 4,292 | 1,663 |
Additional paid in capital | 82,005,259 | 72,879,738 |
Accumulated deficit | (77,732,730) | (68,797,872) |
Total Stockholders’ Equity | 4,276,821 | 4,083,529 |
Common Stock | 4,292 | 1,663 |
Additional Paid In Capital | 82,005,259 | 72,879,738 |
Accumulated Deficit | (77,732,730) | (68,797,872) |
Total Liabilities and Stockholders’ Equity | 4,948,703 | 4,736,605 |